Clinical Trial Update: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection [Phase 2]

View source ↗

Summary

Tonix Pharmaceuticals completed a Phase 2 trial evaluating TNX-102 SL for multi-site pain associated with post-acute sequelae of SARS-CoV-2 infection, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19 | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26